Aro Biotherapeutics

Aro Biotherapeutics is a Philadelphia-based biotechnology company pioneering the development of tissue-targeted genetic medicines using its proprietary Centyrin protein technology. The company develops Centyrin-siRNA conjugates that selectively modulate gene targets in disease tissues to achieve superior efficacy and safety compared to existing approaches. Aro operates both a wholly-owned pipeline and a partnered pipeline of Centyrin-RNA drug conjugates targeting previously intractable diseases, including its lead program ABX1100 for late-onset Pompe disease, which has demonstrated positive Phase 1b clinical results. The company collaborates with industry partners to leverage the Centyrin platform for tissue-specific targeting across a diverse set of rare and serious diseases.